Vimta Labs Ltd Stock Price Today (NSE: VIMTALABS)

Vimta Labs Ltd

543.85+6.75 (+1.26%)
Market Closed

Fundamental Score

...

Vimta Labs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Vimta Labs Ltd share price today is 543.85, up +1.26% on NSE/BSE as of 17 June 2026. Vimta Labs Ltd (VIMTALABS) is a Small-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of 2.72K (Cr). The 52-week high for VIMTALABS share price is 902.65 and the 52-week low is 376.05. At a P/E ratio of 36.39x, VIMTALABS is currently trading below its industry average P/E of 45.95x. The company has a Return on Equity (ROE) of 19.43% and a debt-to-equity ratio of 0.02.

Vimta Labs Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
579.40
Low
435.85
Volume
3.4L
Change
-1.49%

Vimta Labs Ltd share price chart: -1.49% return over the past month. 52-week high ₹902.65, 52-week low ₹376.05.

Vimta Labs Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
456.00472.00451.55469.7081.80K (Cr)
474.00478.50456.40462.151.23L (Cr)
457.05485.00456.05469.703.06L (Cr)
456.70456.70456.70456.700.00 (Cr)
465.00465.00455.00456.7065.96K (Cr)
465.00472.00459.30462.351.05L (Cr)
455.00463.40454.20459.301.07L (Cr)
453.50456.25447.55451.5578.47K (Cr)
452.00457.70448.35450.301.07L (Cr)
450.00453.05443.55449.8099.40K (Cr)

Vimta Labs Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
474.00478.50451.55469.70-0.91%
463.30579.40435.85469.70+1.38%
397.00489.90391.80457.15+15.15%
426.85460.00376.05380.70-10.81%
442.00511.80418.80452.05+2.27%
605.30636.75408.10411.05-32.09%
613.00648.95577.00605.30-1.26%
727.40735.00593.70609.05-16.27%
711.80774.70661.80725.40+1.91%
667.10902.65648.25706.50+5.91%
702.00728.45602.15666.25-5.09%
449.70721.50442.85693.45+54.20%

Returns & Performance

Good

Return on Equity (ROE)

19.43%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

25.22%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

30.85%

Average operating profit margin over 5 years

Dividend Yield

0.16%

Annual dividend as % of current share price

Vimta Labs Ltd Valuation Check

Good

Price to Earnings (P/E)

36.39x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

45.95x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

35.99%

% shares held by company founders/management

Poor

FII Holding

4.33%

% shares held by foreign institutional investors

Poor

DII Holding

0.87%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Good

Profit Growth (Quarterly YoY)

17.04%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

20.19%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

13.74%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

57.82%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

58.03%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.02x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

59.75x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

65.94 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Vimta Labs Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of VIMTALABS across key market metrics for learning purposes.

Positive Indicators

12 factors identified

Strong Return on Equity (19.43%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (25.22%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (30.85%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Attractive Valuation (P/E: 36.39 vs Industry: 45.95)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Strong Revenue Growth (20.19%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Consistent Growth Track Record (13.74% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Excellent EPS Growth (57.82% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (58.03% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.02)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (59.75x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Strong Cash Generation (₹65.94 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

1 factors identified

Limited Institutional Interest (FII+DII: 5.20%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

Vimta Labs Ltd vs Healthcare Research, Analytics & Technology Peers

Peer Comparison - Healthcare Research, Analytics & Technology

Compare Vimta Labs Ltd with 8 other companies in the same sector

9 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
65.8/100
544
₹2716.50
36.4
Average
19.43%
Good
25.22%
Excellent
0.0
Excellent
58.03%
Excellent
13.74%
Good
0.16%
41.6/100
460
₹25985.68
55.5
Average
10.53%
Average
13.52%
Average
0.1
Excellent
5.71%
Good
12.60%
Good
0.19%
66.8/100
519
₹12660.10
28.4
Average
20.59%
Excellent
24.80%
Excellent
0.0
Excellent
67.93%
Excellent
34.59%
Excellent
0.38%
6.5/100
267
₹3927.58
-87.22%
Poor
-86.96%
Poor
0.0
Excellent
-24.19%
Poor
-12.00%
Poor
0.00%
19.5/100
31
₹481.24
120.6
Average
644.12%
Excellent
11.24%
Average
0.0
Excellent
38.14%
Excellent
0.00%
6.9/100
62
₹200.42
-5.58%
Poor
1.10%
Poor
1.5
Average
13.81%
Good
-15.48%
Poor
0.00%
40.6/100
57
₹101.70
104.8
Average
0.64%
Poor
0.96%
Poor
0.0
Excellent
-2.33%
Poor
82.92%
Excellent
0.00%
29.2/100
18
₹25.54
12.3
Average
5.51%
Poor
8.27%
Poor
0.2
Excellent
-1.36%
Poor
8.33%
Good
0.00%
7.2/100
24
₹16.84
-37.24%
Poor
-11.58%
Poor
1.6
Average
-32.27%
Poor
0.00%

Vimta Labs Ltd PE Ratio History

Historical price-to-earnings ratio for VIMTALABS — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202514.93₹605.3040.5x
FY 20249.12₹497.0754.5x
FY 202310.68₹201.7818.9x
FY 20229.16₹218.2023.8x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Vimta Labs Ltd Dividend History

Annual cash dividends paid by VIMTALABS — dividend yield 0.16%

Financial YearDividends Paid (₹ Cr)
FY 20254.43 Cr
FY 20244.43 Cr
FY 20234.42 Cr
FY 20224.42 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Vimta Labs Ltd Quarterly Performance

Latest quarterly metrics for VIMTALABS — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

20.19%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

17.04%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

13.74%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

58.03%

Compounded annual net profit growth over 5 years

Vimta Labs Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for VIMTALABS — calculated from daily price history

27RSI 14
Oversold — RSI 27

Selling pressure is heavy — potential reversal zone.

SMA 50
450
▲ Price above SMA 50 — Short-term bullish
SMA 200
576
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
288K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Vimta Labs Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Vimta Labs Ltd (VIMTALABS) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Vimta Labs Ltd

About VIMTALABS (Vimta Labs Ltd)

Vimta Labs Ltd is a pioneering force within the healthcare research, analytics, and technology landscape, providing a comprehensive suite of services that underpin the advancement ...of medical science and patient care. The company distinguishes itself through its commitment to rigorous scientific methodology, cutting-edge technologies, and a team of highly skilled professionals dedicated to driving innovation. From meticulously designed preclinical studies to expertly managed clinical trials and sophisticated analytical investigations, Vimta Labs serves as a strategic partner for biopharmaceutical companies, medical device manufacturers, and organizations navigating the complexities of healthcare product development. Its focus extends to ensuring the safety and efficacy of healthcare products, empowering its clients to bring innovative solutions to market with confidence. The capabilities of Vimta Labs span the entire healthcare product lifecycle, encompassing early-stage research, clinical development, and post-market surveillance. Employing advanced technologies in genomics, proteomics, and bioinformatics, the company extracts meaningful insights from complex data, accelerating drug discovery and personalized medicine approaches. Their analytical prowess extends to comprehensive quality control and regulatory compliance, helping clients to navigate the intricate web of industry regulations. By combining deep scientific expertise with sophisticated analytical tools, Vimta Labs contributes to informed decision-making, optimized product development strategies, and improved patient outcomes. Its commitment to rigorous testing and insightful data analysis makes it a valuable partner for businesses seeking to ensure the success of their healthcare products. Beyond traditional laboratory services, Vimta Labs embraces technological advancements to enhance its capabilities and deliver integrated solutions. The company leverages sophisticated data analytics platforms, artificial intelligence, and machine learning algorithms to extract valuable insights from large datasets, accelerating research and optimizing clinical trial design. By seamlessly integrating technology with its scientific expertise, Vimta Labs fosters innovation, drives efficiency, and provides its clients with a competitive edge. With a steadfast dedication to scientific excellence, technological innovation, and client satisfaction, Vimta Labs continues to be a trusted partner for companies seeking to transform healthcare through research, analytics, and advanced technology.

Company Details

Symbol:VIMTALABS
Industry:Healthcare Research, Analytics & Technology
Sector:Healthcare Research, Analytics & Technology

Key Leadership

Dr. Sivalinga Prasad Vasireddi
Executive Chairman
Ms. Harita Vasireddi
MD & Whole Time Director
Mr. Siva Rama Krishna Kambhampati
Chief Financial Officer

Corporate Events

Recent
Ex-Dividend Date

VIMTALABS Share Price: Frequently Asked Questions

What is the current share price of Vimta Labs Ltd?

Vimta Labs Ltd (VIMTALABS) trades at ₹543.85 on NSE and BSE. Market cap ₹2.72K (Cr). Educational data only.

What is the P/E ratio of Vimta Labs Ltd?

Vimta Labs Ltd has a P/E of 36.39x vs industry average 45.95x.

What is the Bull Run score for Vimta Labs Ltd?

Vimta Labs Ltd has a Bull Run score of 65.8/100 based on 25+ financial parameters.

Does Vimta Labs Ltd pay dividends?

Vimta Labs Ltd has a dividend yield of 0.16%. Past dividends don't guarantee future payments.

What is the ROE of Vimta Labs Ltd?

Vimta Labs Ltd has ROE of 19.43%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Vimta Labs Ltd?

Vimta Labs Ltd has debt-to-equity of 0.02.

Is Vimta Labs Ltd a good investment?

Bull Run gives Vimta Labs Ltd a score of 65.8/100. This is not investment advice — consult a SEBI-registered advisor.